Search results for "29.0"

showing 10 items of 109 documents

Is There a Future for Non-invasive Brain Stimulation as a Therapeutic Tool?

2019

Several techniques and protocols of non-invasive transcranial brain stimulation (NIBS), including transcranial magnetic and electrical stimuli, have been developed in the past decades. These techniques can induce long lasting changes in cortical excitability by promoting synaptic plasticity and thus may represent a therapeutic option in neuropsychiatric disorders. On the other hand, despite these techniques have become popular, the fragility and variability of the after effects are the major challenges that non-invasive transcranial brain stimulation currentlyfaces. Several factors may account for such a variability such as biological variations, measurement reproducibility, and the neurona…

Long lastingNeuroplasticity; Neuropsychiatric disorders; NIBS; RTMS; TDCSneuroplasticityReviewElectroencephalographytDCSlcsh:RC346-42903 medical and health sciences0302 clinical medicineNeuroplasticityrTMSMedicinelcsh:Neurology. Diseases of the nervous system030304 developmental biologyMeasurement reproducibility0303 health sciencesmedicine.diagnostic_testNIBSbusiness.industryNon invasiveNeuromodulation (medicine)neuropsychiatric disordersNeurologyBrain stimulationSynaptic plasticityNeurology (clinical)businessNeuroscience030217 neurology & neurosurgeryFrontiers in Neurology
researchProduct

Symptom-specific amygdala hyperactivity modulates motor control network in conversion disorder

2016

Initial historical accounts as well as recent data suggest that emotion processing is dysfunctional in conversion disorder patients and that this alteration may be the pathomechanistic neurocognitive basis for symptoms in conversion disorder. However, to date evidence of direct interaction of altered negative emotion processing with motor control networks in conversion disorder is still lacking. To specifically study the neural correlates of emotion processing interacting with motor networks we used a task combining emotional and sensorimotor stimuli both separately as well as simultaneously during functional magnetic resonance imaging in a well characterized group of 13 conversion disorder…

MaleEmotionslcsh:RC346-4290302 clinical medicineddc:150Brain Mappingmedicine.diagnostic_testfMRI05 social sciencesMotor CortexPsychophysiological InteractionRegular ArticleMiddle AgedAmygdalaMagnetic Resonance ImagingFacial ExpressionSubthalamic nucleusmedicine.anatomical_structureNeurologylcsh:R858-859.7FemalePsychologyFacial RecognitionAdultCognitive NeuroscienceEmotion processingPsychogenic paresisMotor Activitylcsh:Computer applications to medicine. Medical informaticsAmygdala050105 experimental psychologyYoung Adult03 medical and health sciencesSubthalamic NucleusmedicineHumans0501 psychology and cognitive sciencesRadiology Nuclear Medicine and imagingMotor networkConversion disorderlcsh:Neurology. Diseases of the nervous systemNeural correlates of consciousnessMotor controlmedicine.diseaseConversion DisorderNeurology (clinical)Functional magnetic resonance imagingNeurocognitiveNeuroscience030217 neurology & neurosurgeryNeuroImage: Clinical
researchProduct

Functional networks of motor inhibition in conversion disorder patients and feigning subjects

2016

The neural correlates of motor inhibition leading to paresis in conversion disorder are not well known. The key question is whether they are different of those of normal subjects feigning the symptoms. Thirteen conversion disorder patients with hemiparesis and twelve healthy controls were investigated using functional magnetic resonance tomography under conditions of passive motor stimulation of the paretic/feigned paretic and the non-paretic hand. Healthy controls were also investigated in a non-feigning condition. During passive movement of the affected right hand conversion disorder patients exhibited activations in the bilateral triangular part of the inferior frontal gyri (IFG), with a…

MaleMotor DisordersAudiologylcsh:RC346-4290302 clinical medicineddc:150Neural PathwaysImage Processing Computer-AssistedYoung adultPrefrontal cortexFeigningParesismedicine.diagnostic_test05 social sciencesfMRIRegular ArticleMiddle AgedMagnetic Resonance ImagingInhibition PsychologicalTreatment OutcomeNeurologyMotor inhibitionlcsh:R858-859.7Femalemedicine.symptomPsychologyAdultmedicine.medical_specialtyImagery PsychotherapyCognitive Neurosciencelcsh:Computer applications to medicine. Medical informatics050105 experimental psychologyFunctional networks03 medical and health sciencesYoung AdultmedicineHumans0501 psychology and cognitive sciencesRadiology Nuclear Medicine and imagingIn patientConversion disorderlcsh:Neurology. Diseases of the nervous systemMagnetic resonance imagingmedicine.diseaseOxygenHemiparesisConversion disorderMotor paresisNeurology (clinical)NeuroscienceConversion disorder ; Motor inhibition ; Feigning ; fMRI ; Motor paresis030217 neurology & neurosurgery
researchProduct

Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving…

2011

Abstract Background Conventional magnetic resonance imaging (MRI) has improved the diagnosis and monitoring of multiple sclerosis (MS). In clinical trials, MRI has been found to detect treatment effects with greater sensitivity than clinical measures; however, clinical and MRI outcomes tend to correlate poorly. Methods In this observational study, patients (n = 550; 18-50 years; relapsing-remitting MS [Expanded Disability Status Scale score ≤4.0]) receiving interferon (IFN) β-1a therapy (44 or 22 µg subcutaneously [sc] three times weekly [tiw]) underwent standardized MRI, neuropsychological and quality-of-life (QoL) assessments over 3 years. In this post hoc analysis, MRI outcomes and corre…

MalePathologyNeurologyDiseaseRelapsing-RemittingNeuropsychological Testslcsh:RC346-4290302 clinical medicineRelapsing-Remitting Multiple Sclerosi030212 general & internal medicine10. No inequalitymedicine.diagnostic_testBrainGeneral MedicineMagnetic Resonance Imaging3. Good healthFemaleSettore MED/26 - NeurologiaRadiologyNeurosurgeryMagnetic Resonance Imaging; Neuroimaging; Immunologic Factors; Dose-Response Relationship Drug; Humans; Brain; Interferon-beta; Quality of Life; Multiple Sclerosis Relapsing-Remitting; Cognition Disorders; Adult; Neuropsychological Tests; Female; MaleDrugInterferon beta-1aResearch ArticleAdultmedicine.medical_specialtyMultiple SclerosisClinical NeurologyNeuroimagingDose-Response Relationship03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingNeuroimagingmedicineImmunologic FactorsHumansNeurochemistrylcsh:Neurology. Diseases of the nervous systemDose-Response Relationship Drugbusiness.industryMultiple sclerosisMagnetic resonance imagingBrain Magnetic Resonance ImagingInterferon-betamedicine.diseaseClinical trialBrain Magnetic Resonance Imaging; Relapsing-Remitting Multiple Sclerosis; Interferon beta-1aQuality of LifeNeurology (clinical)businessCognition Disorders030217 neurology & neurosurgery
researchProduct

Two distinct phenotypes, hemiplegic migraine and episodic Ataxia type 2, caused by a novel common CACNA1A variant

2020

Abstract Background To investigate the genetic and environmental factors responsible for phenotype variability in a family carrying a novel CACNA1A missense mutation. Mutations in the CACNA1A gene were identified as responsible for at least three autosomal dominant disorders: FHM1 (Familial Hemiplegic Migraine), EA2 (Episodic Ataxia type 2), and SCA6 (Spinocerebellar Ataxia type 6). Overlapping clinical features within individuals of some families sharing the same CACNA1A mutation are not infrequent. Conversely, reports with distinct phenotypes within the same family associated with a common CACNA1A mutation are very rare. Case presentation A clinical, molecular, neuroradiological, neuropsy…

MaleProbandmedicine.medical_specialtyNeurologyMigraine with AuraFamilial hemiplegic migraine type 1Mutation MissenseneuropsychologyCase Reportmedicine.disease_causeNystagmus Pathologiclcsh:RC346-42903 medical and health sciences0302 clinical medicinemedicineHumansSpinocerebellar ataxia type 6Missense mutationFamilyChildFamilial hemiplegic migrainelcsh:Neurology. Diseases of the nervous system030304 developmental biologyEpisodic ataxiaGenetics0303 health sciencesMutationbusiness.industryCACNA1A geneEpisodic ataxia type2Cognitive affective syndromeGeneral Medicinemedicine.diseasePhenotypePhenotypeAtaxiaCalcium ChannelsNeurology (clinical)businessCognitive affective syndrome neuropsychology.030217 neurology & neurosurgeryBMC Neurology
researchProduct

Increase of Substance P Concentration in Saliva after Pharyngeal Electrical Stimulation in Severely Dysphagic Stroke Patients – an Indicator of Decan…

2017

Background/Aims: Substance P (SP) is a neuropeptide, likely acting as a neurotransmitter in the pharyngeal mucosa enhancing the swallow and cough reflex. Pharyngeal Electrical Stimulation (PES) induces a temporary increase of salivary SP levels in healthy adults. Previous evidence suggests that post-stroke dysphagia is related to reduced SP levels. Here, we investigated the effects of PES on SP levels in severely dysphagic stroke patients and a possible link between increase of SP and treatment success. Methods: 23 tracheotomized stroke patients who could not be decannulated due to severe and persisting dysphagia according to endoscopic evaluation received PES for 10 minutes a day over thre…

MaleSalivaStroke patientCough reflexStimulationSubstance PSubstance Plcsh:RC346-42903 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compoundTracheostomy0302 clinical medicinePharyngeal electrical stimulationDevelopmental NeurosciencemedicineHumansProspective Studies030212 general & internal medicineSalivaStrokelcsh:Neurology. Diseases of the nervous systemAgedAged 80 and overbusiness.industrylcsh:QP351-495Middle Agedmedicine.diseaseDysphagiaElectric StimulationStrokePESlcsh:Neurophysiology and neuropsychologyNeurologychemistryAnesthesiaTracheal decannulationPharynxBiomarker (medicine)Femalemedicine.symptomDeglutition Disordersbusiness030217 neurology & neurosurgeryNeurosignals
researchProduct

Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin

2009

The dual role of the inducible NO synthase (iNOS) and NO signaling in head and neck squamous cell carcinoma (HNSCC) is a complex and can both promote or inhibit tumor progression. However, the underlying molecular mechanisms are not yet resolved in detail. We show for the first time that conditions, favoring low NO levels conferred resistance against cisplatin/taxol-induced apoptosis in HNSCC cell lines. Cytoprotection was mediated by survivin, because we observed its upregulation subsequent to low doses of the NO donors S-nitroso-N-acetyl-penicillamine (SNAP) and sodium nitroprusside (SNP) or ectopic expression of physiologic amounts of iNOS. Also, RNAi-mediated depletion of survivin block…

MaleUmbilical VeinsCancer ResearchSurvivinFluorescent Antibody TechniqueNitric Oxide Synthase Type IIApoptosisp38 Mitogen-Activated Protein KinasesInhibitor of Apoptosis ProteinsImmunoenzyme TechniquesPhosphatidylinositol 3-Kinaseschemistry.chemical_compoundLY294002Enzyme InhibitorsRNA Small InterferingAged 80 and overReverse Transcriptase Polymerase Chain ReactionCell CycleMiddle AgedCell cycleOncologyHead and Neck NeoplasmsCarcinoma Squamous CellFemaleMicrotubule-Associated ProteinsNitroprussidePaclitaxelImmunoblottingAntineoplastic AgentsS-Nitroso-N-AcetylpenicillamineBiologyCell LineDownregulation and upregulationSurvivinmedicineHumansNitric Oxide DonorsRNA MessengerneoplasmsProtein kinase BNitritesPI3K/AKT/mTOR pathwayAgedmedicine.diseaseAntineoplastic Agents PhytogenicHead and neck squamous-cell carcinomachemistryDrug Resistance NeoplasmTumor progressionImmunologyCancer researchEndothelium VascularCisplatinProto-Oncogene Proteins c-aktInternational Journal of Cancer
researchProduct

Drug connectivity mapping and functional analysis reveal therapeutic small molecules that differentially modulate myelination

2022

Disruption or loss of oligodendrocytes (OLs) and myelin has devastating effects on CNS function and integrity, which occur in diverse neurological disorders, including Multiple Sclerosis (MS), Alzheimer’s disease and neuropsychiatric disorders. Hence, there is a need to develop new therapies that promote oligodendrocyte regeneration and myelin repair. A promising approach is drug repurposing, but most agents have potentially contrasting biological actions depending on the cellular context and their dose-dependent effects on intracellular pathways. Here, we have used a combined systems biology and neurobiological approach to identify compounds that exert positive and negative effects on olig…

MyelinMiceMyelin SheathNSC Neural stem cellSystems BiologyOPC Oligodendrocyte progenitor cellHigh-Throughput Nucleotide SequencingLINCS The Library of Integrated Network-based Cellular SignaturesCell DifferentiationGeneral MedicineCNS Central Nervous SystemOligodendrogliamedicine.anatomical_structureOligodendrogenesisNFOL Newly formed oligodendrocyteOL OligodendrocyteSignal TransductionSubventricular zoneOptic nerveIn silicoSystems biologyMorpholinesSVZ subventricular zoneContext (language use)RM1-950BiologyArticlemedicinePharmacogenomics The Library of Integrated Network-Based Cellular Signatures/LINCSAnimalsH-LY29 High concentration of LY294002Computer SimulationPI3K/AKT/mTOR pathwayL-LY29 Low concentration of LY294002PharmacologyPI3K/AktTCN TriciribineDose-Response Relationship DrugRegeneration (biology)Multiple sclerosismedicine.diseaseOligodendrocyteOligodendrocyteiNSCs iPSC-derived NSCsTAPs Transiently amplifying progenitorsMice Inbred C57BLMS Multiple SclerosisiPCS induced Pluripotent Stem CellChromonesPharmacogeneticsTherapeutics. PharmacologyMOL Myelinating oligodendrocyteNeuroscienceBiomedicine & Pharmacotherapy
researchProduct

CCDC 1577820: Experimental Crystal Structure Determination

2018

Related Article: Zoran Džolić, Ngong Kodiah Beyeh, Mario Cetina, Lotta Turunen, Kari Rissanen|2018|Chem.Asian J.|13|164|doi:10.1002/asia.201701426

N1N1'N1''N1'''-{[2122232-tetraethyl-10203040-tetrahydroxy-5152535-tetraoxa-7172737-tetraazanonacyclo[31.7.1.1311.11321.12331.049.01419.02429.03439]tetratetraconta-1(41)3911(44)131921(43)232931(42)3339-dodecaene-7172737-tetrayl]tetrapropane-31-diyl}tetrakis(N2-phenylethanediamide) chloroform unknown solvate hemihydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

"Table 2" of "Measurement of the Antilambda polarization in nu/mu charged current interactions in the NOMAD experiment."

1993

Lambdabar polarization in regions of the Bjorken scaling variable X.

POLInclusiveNUMU NUCLEON --> MU- LAMBDABAR XStrange productionPolarizationDeep Inelastic ScatteringCharged CurrentMuon production0.938-29.07
researchProduct